--- title: "UBS lowers the target price for SINO BIOPHARM to 11 yuan, rating it as \"Buy\"" type: "News" locale: "zh-HK" url: "https://longbridge.com/zh-HK/news/280955823.md" description: "UBS has lowered the target price for SINO BIOPHARM to 11 yuan, maintaining a \"Buy\" rating. The report pointed out that last year the company's revenue was 31.8 billion yuan, a year-on-year increase of 10.3%, which was below expectations; net profit was 2.3 billion yuan, a year-on-year increase of 22%, also below expectations. The gross profit margin rose to 82.1%. Management expects double-digit growth in both revenue and profit this year. Although the earnings per share forecast for this year has been raised by 9.4%, the earnings per share forecasts for 2027 and 2028 have been lowered due to lower expectations for generic drug revenue" datetime: "2026-03-30T04:28:03.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/280955823.md) - [en](https://longbridge.com/en/news/280955823.md) - [zh-HK](https://longbridge.com/zh-HK/news/280955823.md) --- > 支持的語言: [简体中文](https://longbridge.com/zh-CN/news/280955823.md) | [English](https://longbridge.com/en/news/280955823.md) # UBS lowers the target price for SINO BIOPHARM to 11 yuan, rating it as "Buy" UBS published a research report indicating that SINO BIOPHARM (01177.HK) had a revenue of RMB 31.8 billion last year, an increase of 10.3% year-on-year, which was below expectations; net profit reached RMB 2.3 billion, a year-on-year increase of 22%, also below expectations; gross profit margin increased by 0.6 percentage points year-on-year to 82.1%. Management expects that driven by the continuous growth of innovative products, revenue and profit will achieve double-digit growth this year. The bank raised its earnings per share forecast for SINO BIOPHARM this year by 9.4%, but lowered its earnings per share forecasts for 2027 and 2028 due to lower expectations for revenue and profitability from generic drugs. Additionally, it lowered the company's target price from HKD 12.2 to HKD 11 and reiterated its "Buy" rating ### 相關股票 - [Minsheng Royal CSI Biotechnology Theme ETF (516930.CN)](https://longbridge.com/zh-HK/quote/516930.CN.md) - [ChinaAMC Hang Seng Biotechnology Technology ETF(QDII) (159892.CN)](https://longbridge.com/zh-HK/quote/159892.CN.md) - [Ping An CSI Medicine and Medical Device Innovation ETF (516820.CN)](https://longbridge.com/zh-HK/quote/516820.CN.md) - [Bosera Hang Seng SCHK Innovative Drug Select ETF (520690.CN)](https://longbridge.com/zh-HK/quote/520690.CN.md) - [E Fund CSI Biotechnology Theme ETF (159837.CN)](https://longbridge.com/zh-HK/quote/159837.CN.md) - [China Southern Hang Seng Biotech ETF(QDII) (159615.CN)](https://longbridge.com/zh-HK/quote/159615.CN.md) - [ChinaAMC SSE STAR Biology and Medicine ETF (588130.CN)](https://longbridge.com/zh-HK/quote/588130.CN.md) - [ChinaAMC CSI Biotechnology Theme ETF (516500.CN)](https://longbridge.com/zh-HK/quote/516500.CN.md) - [Yinhua CSI Innovative Drugs Industry ETF (159992.CN)](https://longbridge.com/zh-HK/quote/159992.CN.md) - [Dacheng CSI All Share Health Care Equipment and Services ETF (516610.CN)](https://longbridge.com/zh-HK/quote/516610.CN.md) - [Tianhong CNI BIOMEDICINE ETF (159859.CN)](https://longbridge.com/zh-HK/quote/159859.CN.md) - [China Universal 800 Health Care ETF (159929.CN)](https://longbridge.com/zh-HK/quote/159929.CN.md) - [Guotai CSI Bio-medicine ETF (512290.CN)](https://longbridge.com/zh-HK/quote/512290.CN.md) - [Huaan Hang Seng Biotech ETF (159102.CN)](https://longbridge.com/zh-HK/quote/159102.CN.md) - [Fullgoal Hang Seng SCHK Innovative Drug & Healthcare ETF (159506.CN)](https://longbridge.com/zh-HK/quote/159506.CN.md) - [Lishengpharma (002393.CN)](https://longbridge.com/zh-HK/quote/002393.CN.md) - [Penghua SSE STAR Biology and Medicine ETF (588250.CN)](https://longbridge.com/zh-HK/quote/588250.CN.md) - [科兴生物制药股份有限公司 (25317.HK)](https://longbridge.com/zh-HK/quote/25317.HK.md) - [E Fund CSI 300 Health Care ETF (512010.CN)](https://longbridge.com/zh-HK/quote/512010.CN.md) - [SBP GROUP (01177.HK)](https://longbridge.com/zh-HK/quote/01177.HK.md) - [China Merchants CSI Biotechnology Theme ETF (159849.CN)](https://longbridge.com/zh-HK/quote/159849.CN.md) - [Guotai SSE STAR Brand Name Drug ETF (589720.CN)](https://longbridge.com/zh-HK/quote/589720.CN.md) - [ChinaAMC SSE Health Care ETF Initiating Fund (510660.CN)](https://longbridge.com/zh-HK/quote/510660.CN.md) - [Hwabao WP Hang Seng SCHK Innovative Drug Select ETF (520880.CN)](https://longbridge.com/zh-HK/quote/520880.CN.md) - [E Fund Hang Seng SCHK Innovative Drug ETF (159316.CN)](https://longbridge.com/zh-HK/quote/159316.CN.md) - [ICBCCS SSE STAR Biology and Medicine ETF (588860.CN)](https://longbridge.com/zh-HK/quote/588860.CN.md) - [Founder Fubon CSI Medicine and Medical Device Innovation ETF (560600.CN)](https://longbridge.com/zh-HK/quote/560600.CN.md) ## 相關資訊與研究 - [Junshi Biosciences Chairman Completes RMB100 Million Shareholding Increase](https://longbridge.com/zh-HK/news/281231901.md) - [Biocytogen and Sihuan partner to advance new therapeutics for weight loss](https://longbridge.com/zh-HK/news/281501537.md) - [Annovis Bio Director Purchased Shares Worth Over $1.4M](https://longbridge.com/zh-HK/news/281662341.md) - [RemeGen Receives Chinese Regulatory Nod for RC288 Clinical Trial](https://longbridge.com/zh-HK/news/281458440.md) - [CICC Remains a Buy on Yonghe Medical Group Co., Ltd. (2279)](https://longbridge.com/zh-HK/news/281703443.md)